Smith, Moore & Co.
- SEC CIK
- 0000200724
- Latest filing
- Aug 12, 2026
EXC holding history
Exelon Corp in every 13F filed by Smith, Moore & Co., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
EXC overviewAll 13F holders of EXCFull Q2 2026 holdings
- Shares (Q2 2026)
- 5,509
- Value
- $256.8K
- % of portfolio
- <0.1%
- Quarters held
- 19
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 5,509 | $256.8K | <0.1% | +20+0.4% | Added | Holders |
| Q1 2026 | 5,489 | $269.0K | <0.1% | +19+0.3% | Added | Holders |
| Q4 2025 | 5,470 | $238.4K | <0.1% | −41−0.7% | Reduced | Holders |
| Q3 2025 | 5,511 | $248.1K | <0.1% | +146+2.7% | Added | Holders |
| Q2 2025 | 5,365 | $232.9K | <0.1% | −132−2.4% | Reduced | Holders |
| Q1 2025 | 5,497 | $253.3K | <0.1% | +20+0.4% | Added | Holders |
| Q4 2024 | 5,477 | $206.2K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 5,477 | $222.1K | <0.1% | +5,477 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −5,637−100.0% | Sold out | Holders |
| Q1 2024 | 5,637 | $211.8K | <0.1% | +5,637 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −5,220−100.0% | Sold out | Holders |
| Q2 2023 | 5,220 | $212.7K | <0.1% | −550−9.5% | Reduced | Holders |
| Q1 2023 | 5,770 | $241.7K | <0.1% | −100−1.7% | Reduced | Holders |
| Q4 2022 | 5,870 | $253.8K | <0.1% | +61+1.1% | Added | Holders |
| Q3 2022 | 5,809 | $218.0K | <0.1% | −858−12.9% | Reduced | Holders |
| Q2 2022 | 6,667 | $302.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 6,667 | $318.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 6,667 | $385.0K | 0.1% | −1,681−20.1% | Reduced | Holders |
| Q3 2021 | 8,348 | $404.0K | 0.1% | +393+4.9% | Added | Holders |
| Q2 2021 | 7,955 | $352.0K | 0.1% | 00.0% | Unchanged | Holders |
| Q1 2021 | 7,955 | $348.0K | 0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.